Related Topics News -

     
 Title only   |   Print    Next page > 
     
《大行》大摩列康龍化成為中型CRO/CDMO首選股 長期看好昭衍泰格

2025-06-10T  
《業績》凱萊英首季淨利潤3.27億人民幣 增長15.8%

2025-04-23T  
《大行》里昂調整醫藥股目標價 內地CXO及創新藥物表現亮麗

2025-04-08T  
《業績》凱萊英去年純利9.49億人幣跌58.2% 每股派息1.1元人幣

2025-03-31T  
《大行》麥格理對中國CDMO及生物科技股投資評級及目標價(表)

2025-03-25T  
《大行》麥格理看好生物科技股多於CDMO 首選百濟神州及基石藥業

2025-03-25T  
凱萊英醫藥高級管理人員肖毅退休

2025-03-07T  
凱萊英累計回購1,230萬股A股 總金額10億人民幣

2025-02-19T  
《盈警》凱萊英預報全年淨利潤下降54%-63%

2025-01-28T  
凱萊英首席科學官退休 將獲聘為顧問

2024-12-20T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.